Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bromfenac A · 1 trial · 1 indication
The Ocular Surface Disease Index (OSDI) is a 12 item questionnaire. Each question about discomfort/limitations is scored from 0 to 4, with 0 being 'None of the Time' and 4 being 'All of the Time'. The minimum total score is 0 and the maximum total score is 48, with higher scores indicating worse outcomes.
| Arm | Type | Description |
|---|---|---|
| Bromfenac Ophthalmic Solution A | EXPERIMENTAL | Bromfenac ophthalmic solution A |
| Bromfenac Ophthalmic Solution B | EXPERIMENTAL | Bromfenac ophthalmic solution B |
| Placebo Comparator | PLACEBO_COMPARATOR | Placebo Comparator |
| Name | Type | Description |
|---|---|---|
| Bromfenac Ophthalmic Solution A | DRUG | sterile ophthalmic solution |
| Bromfenac Ophthalmic Solution B | DRUG | sterile ophthalmic solution |
| Placebo Comparator | DRUG | sterile ophthalmic solution |
Inclusion Criteria: * Be of either gender and any race 18 years or older Exclusion Criteria: * Have a local or systemic disease that could interfere with the assessment of safety or efficacy or that is likely to result in early discontinuation from the study
Bromfenac A is an investigational small molecule being developed for the treatment of Dry Eye Syndrome. It is formulated as an ophthalmic solution and is currently in Phase 3 clinical development. The drug is being studied for its safety and efficacy in patients with this condition.
Bromfenac A is being developed by Bausch + Lomb Corporation, a company traded on the stock exchange under the ticker symbol BLCO. The company is conducting clinical research on this ophthalmic solution for Dry Eye Syndrome.
Bromfenac A is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 3 trial has been completed to evaluate its safety and efficacy in patients with Dry Eye Syndrome.
Bromfenac A has one completed Phase 3 clinical trial registered as NCT01212471. This was a dose-ranging study that evaluated the safety and efficacy of Bromfenac ophthalmic solution in Dry Eye Disease. The trial enrolled 840 participants in the United States and was randomized, double-blind, and placebo-controlled.
Bromfenac A is a specific formulation of bromfenac, a nonsteroidal anti-inflammatory drug, developed as an ophthalmic solution for Dry Eye Syndrome. While the active ingredient is bromfenac, Bromfenac A refers to this particular investigational product being studied by Bausch + Lomb.